New prescriptions for Wegovy among teenagers increased by 50% between 2023 and 2024, according to a June 3 report from healthcare data company Truveta. To analyze GLP-1 utilization trends among ...

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival Wegovy from Novo Nordisk. The full data from the 751-subject SURMOUNT-5 ...

A huge market for compounded versions of Wegovy and rival therapy Zepbound (tirzepatide) from Eli Lilly sprang up while the two drugs were having supply constraints, with both companies trying to ...

Some Blue Cross and Blue Shield insurers dipped their toes into expanding coverage for blockbuster weight-loss drugs, then ...

Entering text into the input field will update the search result below Home page Seeking Alpha - Power to Investors Search for Symbols, analysts, keywords ...

The findings of a new study lend support for type 1 diabetes autoantibody screening in people with other autoimmune conditions to prevent complications such as diabetic ketoacidosis.